薬の現象学

出版社： 丸善出版
著者：
発行日： 2022-01-30
分野： 薬学  >  薬学一般
ISBN： 9784621306901
電子書籍版： 2023-01-30 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,300 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,300 円(税込)

購入する

商品紹介

「薬を飲む」とは，「薬が効く」とは，どういうことなのか
薬剤師として，気鋭のEBM研究者として，薬の社会教育者として，蓄積してきた「薬と生活」「薬とその効果」をめぐる科学哲学．
エビデンスを踏まえつつ薬に関する非科学的・非合理的な側面を言語化し，根源的な問いについて思索する存在・認識・情動・生活をめぐる珠玉のエッセイ

目次

  • 1部　存　在――夜空には何が「ある」のか
    　1章　薬に効果が「ある」といったときの「ある」について
    　2章　薬剤効果の感覚質
    　3章　統計世界と生活世界

    2部　認　識――解釈に対する眼差し、あるいは正当性の論理
    　4章　情報が表しているもの
    　5章　メディアとバイアスとスピン
    　6章　トンデモ医療と正統医療の線引き問題

    3部　情　動――臨床をめぐる中動態
    　7章　薬を飲まない・飲めない問題
    　8章　生活の中の依存と医療
    　9章　ポリファーマシーを問題にすることの問題

    4部　生　活――医療と暮らしのはざまで
    　10章　日常と非日常をめぐる変化の中で
    　11章　淡い西陽が差し込む午後の病棟で
    　最終章　「健康」に対する概念的諸連関の展開

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1部 存在 - 夜空には何が「ある」のか

P.21 掲載の参考文献
1) 鴨長明. 方丈記(https://www.aozora.gr.jp/cards/000196/files/975_15935.html)
 
2) ジョン・エリス・マクタガート. 永井 均訳. 時間の非実在性(講談社学術文庫). 東京:講談社;2017.
 
3) 入不二基義. 時間は実在するか(講談社現代新書). 東京:講談社;2002.
 
4) アイザック・ニュートン. 中野猿人訳. プリンシピア 自然哲学の数学的原理. 第1編 物体の運動(ブルーバックス). 東京:講談社;2019.
 
5) 野家啓一. 歴史を哲学する-七日間の集中講義(岩波現代文庫). 東京:岩波書店;2016.
 
6) 野家啓一. 物語の哲学. 増補版(岩波現代文庫). 東京:岩波書店;2005.
 
7) 中島義道. 差別感情の哲学(講談社学術文庫). 東京:講談社;2015.
 
8) 伊勢田哲治. 動物からの倫理学入門. 名古屋:名古屋大学出版会;2008.
 
9) 國分功一郎. 暇と退屈の倫理学. 増補新版. 東京:太田出版;2015.
 
10) ハンス・クリスチャン・アンデルゼン. 菊池 寛訳. 醜い家鴨の子(https://www.aozora.gr.jp/cards/000019/files/42386_21530.html)
 
11) Watanabe S. Knowing and guessing:A quantitative study of inference and Information. John Wiley & Sons 1969.
 
12) Watanabe S. Epistemological relativity. Logico-linguistic source of relativity. Annals of the Japan Association for Philosophy of Science 1986;7:1-14.
 
13) 伊坂幸太郎. 終末のフール(集英社文庫). 東京:集英社;2009.
 
P.41 掲載の参考文献
1) マルクス・ガブリエル. 姫田多佳子訳. 「私」は脳ではない-21世紀のための精神の哲学(講談社選書メチエ). 東京:講談社;2019.
 
2) マルクス・ガブリエル. 清水一浩訳. なぜ世界は存在しないのか(講談社選書メチエ). 東京:講談社;2018.
 
3) B. C. ファン・フラーセン. 丹治信春訳. 科学的世界像. 東京:紀伊國屋書店;1986.
 
4) 伊勢田哲治. 科学的実在論はどこへ向かうのか. Nagoya Journal of Philosophy 2005;4:35-50(http://tiseda.sakura.ne.jp/works/realism.html).
 
5) 戸田山和久. 科学的実在論を擁護する. 名古屋:名古屋大学出版会;2015.
 
6) 野家啓一. 科学の解釈学(講談社学術文庫). 東京:講談社;2013.
 
7) Vickers AV, Vertosick EA, et al. Acupuncture for chronic pain:Update of an individual patient data meta-analysis. J Pain 2018;19:455-74.
 
8) Marmot M, Allen JJ. Social determinants of health equity. Am J Public Health 2014;104:S517-9.
PubMed
9) Carvalho C, Caetano JM, et al. Open-label placebo treatment in chronic low back pain:a randomized controlled trial. Pain 2016;157:2766-72.
PubMed
10) Mok TS, WuY-L, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcino-ma. N Engl J Med 2009;361:947-57.
 
11) Pan Y, Meister R, et al. Open-label placebos for menopausal hot flushes:a randomized controlled trial. Sci Rep 2020;10:20090.
PubMed
12) Rief W, Nestoriuc Y, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials:a systematic review and meta-analysis. Drug Saf 2009;32:1041-56.
PubMed
13) Kaptchuk TJ, Friedlander E, et al. Placebos without deception:a randomized controlled trial in irritable bowel syndrome. PLoS One 2010;5:e15591.
PubMed
14) Schaefer M, Sahin T, et al. Why do open-label placebos work? A randomized controlledtrial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis. PLoS One 2018;13:e0192758.
 
15) Hoenemeyer TW, Kaptchuk TJ, et al. Open-label placebo treatment for cancer-related fatigue:A randomized-controlled clinical trial. Sci Rep 2018;8:2784.
PubMed
16) Fletcher C, Wilson C, et al. The relationship between anticipated response and subsequent experience of cancer treatment-related side effects:A meta-analysis comparing effects before and after treatment exposure. Cancer Treat Rev 2018;68:86-93.
PubMed
17) Smith LE, Webster RK, et al. A systematic review of factors associated with side-effect expectations from medical interventions. Health Expect 2020;23:731-58.
PubMed
18) Rosenthal R, Jacobson L. Pygmalion in the classroom:Teacher expectation and pupils' intellectual development. Canada:Holt, Rinehart & Winston;1968.
 
19) Mayo E. The human problems of an industrial civilization. New York:Macmillan;1933.
 
20) Simpson SH, Eurich DT, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15.
PubMed
21) Patrick AR, Shrank WH, et al. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health 2011;14:513-20.
 
22) Dormuth CR, Patrick AR, et al. Statin adherence and risk of accidents:A cautionary tale. Circulation 2009;119:2051-7.
PubMed
P.73 掲載の参考文献
1) 古田徹也. 不道徳的倫理学講義-人生にとって運とは何か(ちくま新書). 東京:筑摩書房;2019.
 
2) Roush SW, Murphy TV, et al. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007;298:2155-63.
PubMed
3) Orenstein WA, Ahmed R. Simply put:Vaccination saves lives. Proc Natl Acad Sci U S A 2017;114:4031-3.
PubMed
4) Miller RG, Secrest AM, et al. Improvements in the life expectancy of type 1 diabetes:The Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 2012;61:2987-92.
PubMed
5) Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013:a collaborative analysis of cohort studies. Lancet HIV 2017;4:e349-56.
PubMed
6) 厚生労働省. 平成29年(2017)人口動態統計(確定数)の概況:主要統計表(最新データ, 年次推移)(https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kaku-tei17/index.html)
 
7) Suissa S, Ernst P, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6.
PubMed
8) Kang JY, Elders A, et al. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther 2006;24:65-79.
PubMed
9) Gage BF, Waterman AD, et al. Validation of clinical classification schemes forpredicting stroke:Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
 
10) Lopez-Lopez JA, Sterne JAC, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation:systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017;359:j5058.
PubMed
11) Singer DE, Chang Y, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151:297-305.
PubMed
12) Chao T-F, Chiang C-E, et al. Evolving changes of the use of oral anticoagulants and outcomes in patients with newly diagnosed atrial fibrillation in Taiwan. Circulation 2018;138:1485-7.
PubMed
13) Taylor F, Huffman MD, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(1):CD004816.
PubMed
14) Zinman B, Wanner C, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
PubMed
15) Neal B, Perkovic V, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
PubMed
16) Naylor CD, Chen E, et al. Measured enthusiasm:does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-21.
PubMed
17) Polack FP, Thomas SJ, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-15.
PubMed
18) Laupacis A, Sackett DL, et al. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
PubMed
19) Cook RJ, Sackett DL. The number needed to treat:A clinically useful measure of treatment effect. BMJ 1995;310:452-4.
 
20) Nakamura H, Arakawa K, et al. Primary prevention of cardiovascular disease with pravastatin in Japan( MEGA Study ):A prospective randomised controlled trial. Lancet 2006;368:1155-63.
PubMed
21) McAlister FA. The "number needed to treat" turns 20-and continues to be used and misused. CMAJ 2008;179:549-53.
PubMed
22) Gueyffier F, Boutitie F, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997;126:761-7.
 
23) Lei J, Ploner A, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020;383:1340-8.
PubMed

2部 認識 - 解釈に対する眼差し、あるいは正当性の論理

P.83 掲載の参考文献
1) 宇野常寛. 遅いインターネット(NewsPicks Book). 東京:幻冬舎;2020.
 
2) 法務省:犯罪白書. 令和元年版 犯罪白書(http://hakusyo1.moj.go.jp/jp/66/nfm/n66_2_2_2_1_3.html)
 
3) 戸田山和久. 教養の書. 東京:筑摩書房;2020.
 
P.97 掲載の参考文献
1) Paiva CE, Lima JP, et al. Articles with short titles describing the results are cited more often. Clinics(Sao Paulo)2012;67:509-13.
PubMed
2) Njire Braticevic M, Babic I, et al. Title does matter:a cross-sectional study of 30 journals in the Medical Laboratory Technology category. Biochem Med(Zagreb) 2020;30:010708.
 
3) Habibzadeh F, Yadollahie M, et al. Are shorter article titles more attractive for cita-tions? Cross-sectional study of 22 scientific journals. Croat Med J 2010;51:165-70.
 
4) Lundh A, Barbateskovic M, et al. Conflicts of interest at medical journals:The influence of industry-supported randomised trials on journal impact factors and revenue-cohort study. PLoS Med 2010;7:e1000354.
PubMed
5) Handel AE, Patel SV, et al. High reprint orders in medical journals and pharmaceutical industry funding:Case-control study. BMJ 2012;344:e4212.
 
6) Polack FP, Thomas SJ, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-15.
PubMed
7) Boutron I, Dutton S, et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303:2058-64.
PubMed
8) Khan MS, Lateef N, et al. Level and prevalence of spin in published cardiovascular randomized clinical trial reports with statistically nonsignificant primary outcomes:A systematic review. JAMA Netw Open 2019;2:e192622.
PubMed
9) Als-Nielsen B, Chen W, et al. Association of funding and conclusions in randomized drug trials:a reflection of treatment effect or adverse events? JAMA 2003;290:921-8.
PubMed
10) Friedman LS, Richter ED. Relationship between conflicts of interest and research results. J Gen Intern Med 2004;19:51-6.
 
11) Bhandari M, Busse JW, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004;170:477-80.
PubMed
12) Chiu K, Grundy Q, et al. 'Spin' in published biomedical literature:A methodological systematic review. PLoS Biol 2017;15:e2002173.
PubMed
13) Lieb K, von der Osten-Sacken J, et al. Conflicts of interest and spin in reviews of psychological therapies:A systematic review. BMJ Open 2016;6:e010606.
 
14) Bero L, Chiu K, et al. The SSSPIN study-spin in studies of spin:Meta-research analysis. BMJ 2019;367:l6202.
PubMed
15) 野家啓一. 科学哲学への招待(ちくま学芸文庫). 東京:筑摩書房;2015. pp.189.
 
16) 野家啓一. パラダイムとは何か(講談社学術文庫). 東京:講談社;2008. pp.149.
 
P.110 掲載の参考文献
1) 野家啓一. 科学哲学への招待(ちくま学芸文庫). 東京:筑摩書房;2015. pp.112-8, pp.152-5.
 
2) 戸田山和久. 論理学を作る. 名古屋:名古屋大学出版会;2000. p.47.
 
3) 戸田山和久. 科学哲学の冒険サイエンスの目的と方法をさぐる. 東京:NHK出版;2005. p.49.
 
4) W. V. O. クワイン. 飯田 隆訳. 論理的観点から-論理と哲学をめぐる九章(双書プロブレーマタ). 東京:勁草書房;1992.
 
5) Action to Control Cardiovascular Risk in Diabetes Study Group.Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
 
6) 五十嵐涼介. カント論理学の形式的分析(2). 哲学論叢 2018;45:31-46(http://hdl.handle.net/2433/240636
 
7) Qaseem A, Wilt TJ, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus:A guidance statement update from the American College of Physicians. Ann Intern Med 2018;168:569-76.
PubMed
8) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). UK Prospective Diabetes Study(UKPDS) Group.Lancet 1998;352:837-53.
 
9) 青島周一. 視野を広げるエビデンスの読み方-医学論文を読んで活用するための10講義. 東京:中外医学社;2020.
 
10) Sehon SR, Stanley DE, et al. A philosophical analysis of the evidence-based medicine debate. BMCHealth Serv Res 2003;3:14.
PubMed
11) トーマス・クーン. 中山 茂訳. 科学革命の構造. 東京:みすず書房;1971.
 
12) Lakatos I, Musgrave A, editors. Criticism and the growth of knowledge. vol. 4. Proceedings of the international colloquium in the philosophy of science, London, 1965. 1st ed. London:Cambridge University Press;1970.
 
13) 伊勢田哲治. 疑似科学と科学の哲学. 名古屋:名古屋大学出版会;2003.
 
14) カール・R. ポパー. 森 博訳. 客観的知識-進化論的アプローチ. 東京:木鐸社;2004.
 

3部 情動 - 臨床をめぐる中動態

P.132 掲載の参考文献
1) 学校給食法(昭和二十九年法律第百六十号)(https://elaws.e-gov.go.jp/document?lawid=329AC0000000160)
 
2) Miyawaki A, Lee JS, et al. Impactof the school lunch program on overweightand obesity among junior high school students:A nationwide study in Japan. J Public Health(Oxf)2019;41:362-70.
 
3) 安部景奈, 赤松利恵. 小学校における給食の食べ残しに関連する要因の検討. 栄養学雑誌 2011;69:75-81.
Medical*Online
4) 國分功一郎. 中動態の世界-意志と責任の考古学(シリーズ ケアをひらく). 東京:医学書院;2017.
 
5) 國分功一郎. はじめてのスピノザ 自由へのエチカ(講談社現代新書). 東京:講談社;2020.
 
6) Aronson JK. Compliance, concordance, adherence. Br J Clin Pharmacol 2007;63:383-4.
PubMed
7) Naderi SH, Bestwick JP, et al. Adherence to drugs that prevent cardiovascular disease:Meta-analysis on 376, 162 patients. Am J Med 2012;125:882-7.
PubMed
8) Briesacher BA, Andrade SE, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-43.
PubMed
9) Park HY, Seo SA, et al. Medication adherence and beliefs aboutmedication in elderly patients living alone with chronic diseases. Patient Prefer Adherence 2018;12:175-81.
PubMed
10) Chapman S, Dale P, et al. Modelling the effectof beliefs aboutasthma medication andtreatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication. NPJ Prim Care Respir Med 2017;27:61.
 
11) Wei L, Champman S, et al. Beliefs about medicines and non-adherence in patients with stroke, diabetes mellitus and rheumatoid arthritis:a cross-sectional study in China. BMJ Open 2017;7:e017293.
 
12) Chapman SC, Horne R, et al. Patients ' perspectives on antiepileptic medication:Relationships between beliefs about medicines and adherence among patients with epilepsy in UK primary care. Epilepsy Behav 2014;31:312-20.
PubMed
13) Horne R, Chapman SC, et al. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions:A meta-analytic review of the Necessity-Concerns Framework. PLoS One 2013;8:e80633.
PubMed
14) Nieuwlaat R, Wilczynski N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014;(11):CD000011.
PubMed
15) Kripalani S, Yao X, et al. Interventions to enhance medication adherence in chronic medical conditions:A systematic review. Arch Intern Med 2007;167:540-50.
PubMed
P.147 掲載の参考文献
1) 東畑開人. 居るのはつらいよ-ケアとセラピーについての覚書(シリーズ ケアをひらく). 東京:医学書院;2019.
 
2) 橋元良明. ネット依存の現状と課題-SNS依存を中心として. ストレス科学研究 2018;33:10-4(DOI:10.5058/stresskagakukenkyu. 2018005)
 
3) 松本俊彦. 薬物依存症(シリーズ ケアを考える). 東京:筑摩書房;2018. p.323.
 
4) 國分功一郎. 原子力時代における哲学(犀の教室 Liberal Arts Lab). 東京:晶文社;2019.
 
5) Chaiton M, Diemert L, et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open 2016;6:e011045.
 
6) 松本泉美. 20～30歳代女性喫煙者の喫煙の意味と禁煙の意思の構造. 日本看護研究学会雑誌 2011;34:61-72.
 
7) Pechmann C, Delucchi K, et al. Randomised controlled trial evaluation of Tweet2Quit:A social network quit-smoking intervention. Tob Control 2017;26:188-94.
PubMed
8) Hartmann-Boyce J, Chepkin SC, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018;5:CD000146.
PubMed
9) Hu Y, Zong G, et al. Smoking cessation, weight change, type 2 diabetes, and mortality. N Engl J Med 2018;379:623-32.
PubMed
10) Jorenby DE, Hays JT, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation:A randomized controlled trial. JAMA 2006;296:56-63.
PubMed
11) Gonzales D, Rennard SI, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation:A randomized controlled trial. JAMA 2006;296:47-55.
PubMed
12) Hackshaw A, Morris JK, et al. Low cigarette consumption and risk of coronary heart disease and stroke:Meta-analysis of 141 cohort studies in 55 study reports. BMJ 2018;360:j5855.
PubMed
13) Taylor G, McNeill A, et al. Change in mental health after smoking cessation:systematic review and meta-analysis. BMJ 2014;348:g1151.
PubMed
P.160 掲載の参考文献
1) Fries JF. Aging, natural death, and the compression of morbidity. N Engl J Med 1980;303:130-5.
PubMed
2) 厚生労働省. 平成28年簡易生命表の概況(http://www.mhlw.go.jp/toukei/saikin/hw/life/life16/dl/life16-02.pdf)
 
3) Tsuji I. Epidemiologic research on healthy life expectancy and proposal for its extension:A revised English version of Japanese in the Journal of the Japan Medical Association 2019;148:1781-4. JMA J 2020;3:149-53.
PubMed
4) Statistics Bureau of Japan. Current population estimates(http://www.stat.go.jp/english/data/jinsui/2018np/index.html)
 
5) Barnett K, Mercer SW, et al. Epidemiology of multimorbidity and implicationsfor health care, research, and medical education:A cross-sectional study. Lancet 2012;380:37-43.
 
6) Chao TF, Chiang CE, et al. Evolving changesof the use of oral anticoagulantsand outcomesin patientswith newly diagnosed atrial fibrillation in Taiwan. Circulation 2018;138:1485-7.
 
7) Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people:A meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:407-15.
 
8) Taylor F, Huffman MD, et al. Statinsfor the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(1):CD004816.
PubMed
9) Peng J, Liu Y, et al. Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture:A meta-analysis. Pak J Med Sci 2016;32:499-504.
PubMed
10) Byun J-H, Jang S, et al. The efficacy of bisphosphonates for prevention of osteoporotic fracture:An update meta-analysis. J Bone Metab 2017;24:37-49.
PubMed
11) Beckett NS, PetersR, et al. Treatment of hypertension in patients80 yearsof age or older. N Engl J Med 2008;358:1887-98.
PubMed
12) Onoue H, Koyama T, et al. Trendsin polypharmacy in Japan:A nationwide retrospective study. J Am Geriatr Soc 2018;66:2267-73.
 
13) Amano H, Fujimoto K, et al. The prevalence and characteristics of older japanese adults with polypharmacy, based on regionally representative health insurance claims data. Acta Med Okayama 2020;74:41-8.
PubMed
14) Mabuchi T, Hosomi K, et al. Polypharmacy in elderly patients in Japan:Analysis of Japanese real-world databases. J Clin Pharm Ther 2020;45:991-6.
PubMed
15) Suzuki T, Iwagami M, et al. Number of consulting medical institutions and risk of polypharmacy in community-dwelling older people under a healthcare system with free access:A cross-sectional study in Japan. BMC Health Serv Res 2020;20:359.
 
16) 尾藤誠司, 菊地真実. 「なぜ薬が増えていくのか」に関する人類学的・行動経済学的考察. 第10回日本プライマリ・ケア連合学会学術大会 教育講演. 2019(https://confit.atlas.jp/guide/event/woncaaprjpca2019/subject/ELC1-2/advanced?cryptoId=)
 
17) Masnoon N, Shakib S, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17:230.
PubMed
18) Gnjidic D, Hilmer SN, et al. Polypharmacy cutoff and outcomes:Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012;65:989-95.
PubMed
19) 名郷直樹. ポリファーマシーと言われる中で起きていること:構造主義医療の視点から. 第10回日本プライマリ・ケア連合学会学術大会 教育講演. 2019(https://confit.atlas.jp/guide/event/woncaaprjpca2019/subject/ELC1-1/advanced?cryptoId=)
 
20) Benetos A, Labat C, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents:The PARTAGE study. JAMA Intern Med 2015;175:989-95.
PubMed
21) Radholm K, Festin K, et al. Blood pressure and all-cause mortality:A prospective study of nursing home residents. Age Ageing 2016;45:826-32.
PubMed
22) By the 2019 American GeriatricsSociety BeersCriteria(R) Update Expert Panel. J Am Geriatr Soc 2019;67:674-94.
 
23) O'Mahony O, O'Sullivan D, et al. STOPP/START criteria for potentially inappropriate prescribing in older people:Version 2. Age Ageing 2015;44:213-8.
 
24) Hill-Taylor B, Walsh KA, et al. Effectiveness of the STOPP/START(screening tool of older persons' potentially inappropriate prescriptions/screening tool to alert doctors to the right treatment)criteria:Systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther 2016;41:158-69.
 
25) Verdoorn S, Kwint HF, et al. Majority of drug-related problemsidentified duringmedication review are not associated with STOPP/START criteria. Eur J Clin Pharmacol 2015;71:1255-62.
 
26) Schafer I, Kaduszkiewicz H, et al. Narrative medicine-based intervention in primary care to reduce polypharmacy:Results from the cluster-randomised controlled trial MultiCare AGENDA. BMJ Open 2018;8:e017653.
PubMed
27) Ravn-Nielsen LV, Duckert ML, et al. Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission:A randomized clinical trial. JAMA Intern Med 2018;178:375-82.
 

4部 生活 - 医療と暮らしのはざまで

P.172 掲載の参考文献
1) 厚生労働省. 第21回生命表(完全生命表)の概況(https://www.mhlw.go.jp/toukei/saikin/hw/life/21th/dl/21th_02.pdf)
 
2) Keenan PS. Smoking and weight change after new health diagnoses in older adults. Arch Intern Med 2009;169:237-42.
PubMed
3) Schneider KL, Andrews C, et al. Change in physical activity after a diabetes diagnosis:Opportunity for intervention. Med Sci Sports Exerc 2014;46:84-91.
PubMed
4) Kawamori R, Tajima N, et al. Voglibose for prevention of type 2 diabetes mellitus:A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14.
PubMed
5) Hempler NF, Krasnik A, et al. The relationship between changes in health behaviour and initiation of lipid-lowering and antihypertensive medications in individuals at high risk of ischaemic heart disease. BMC Public Health 2012;12:626.
PubMed
6) Korhonen MJ, Pentti J, et al. Lifestyle changes in relation to initiation of antihy-pertensive and lipid-lowering medication:A cohort study. J Am Heart Assoc 2020;9:e014168.
 
P.182 掲載の参考文献
1) Tashkin DP, Celli B, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
PubMed
2) Singh S, Loke YK, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease:Systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215.
PubMed
3) Karner C, Chong J, et al. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;(7):CD009285.
PubMed
P.190 掲載の参考文献
1) Ikeda A, Iso H, et al. The relationships between interest for and participation in health screening and risk of mortality:The Japan Collaborative Cohort Study. Prev Med 2005;41:767-71.
PubMed
2) Krogsboll LT, Jorgensen KJ, et al. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev 2019;1:CD009009.
PubMed
3) Green BL, Lewis RK, et al. Powerlessness, destiny, and control:the influence on health behaviors of African Americans. J Community Health 2004;29:15-27.
PubMed
4) Ishikawa M, Yokoyama T, et al. Subjective well-being is associated with food behavior and demographic factors in chronically ill older Japanese people living alone. J Nutr HealthAging 2018;22:341-53.
 
5) Cabiedes-Miragaya L, Diaz-Mendez C, et al. Well-being and the lifestyle habits of the Spanishpopulation:The association between subjective well-being and eating habits. Int J Environ Res Public Health2021;18:1553.
 
6) 竹田青嗣. 言語的思考へ-脱構築と現象学. 東京:径書房;2001.
 

書評

最近チェックした商品履歴

Loading...